Accelerating the timeline from innovation to access for women

San Francisco, CA   |
GuideStar Charity Check


EIN: 26-4443340


Medicines360 is a non-profit pharmaceutical organization working toward a world where all women have access to the medicines they need. Our mission is to catalyze equitable access to medicines & devices through product development, policy advocacy, and collaboration with U.S. and global partners.

Ruling year info


Principal Officer

Andrea Olariu, MD, PhD

Main address

49 Stevenson Street Suite 1100

San Francisco, CA 94105 USA

Show more contact info



Subject area info

Philanthropy and public policy

Health care access

Reproductive health care


Diseases and conditions

Population served info

Women and girls

NTEE code info

(Research Institutes and/or Public Policy Analysis) (G05)

IRS subsection

501(c)(3) Public Charity

IRS filing requirement

This organization is required to file an IRS Form 990 or 990-EZ.

Tax forms



Programs and results

What we aim to solve

SOURCE: Self-reported by organization

We believe the nonprofit pharma model can help speed the transformation of the healthcare system to ensure equitable access to life-altering medicines. Unbeholden to shareholder interests, our model is catalyzing increased access to affordable medicines that address unmet medical needs for women’s health.

Our programs

SOURCE: Self-reported by organization

What are the organization's current programs, how do they measure success, and who do the programs serve?

Conducting pharmaceutical development to bring new medicines to market

Founded in 2009 because the most effective forms of reversible contraception were too expensive and out of reach, Medicines360 is a nonprofit pharmaceutical organization that prioritizes women over profit to ensure equitable access to medicines.

Today, our focus is to develop and provide a broader range of high-quality products that will help fill gaps in women’s health. Our experience in drug development, clinical trial research, and regulatory affairs makes us uniquely positioned to address the high cost of medicines in the U.S and globally.

Medicines360 has products called LILETTA® and AVIBELA™ that are available in many countries and regions, but not all.

Population(s) Served

Continually assess the market to identify barriers women face in accessing the health products they need.

Population(s) Served

Forming key relationships with nonprofits, pharmaceutical companies, and global non-governmental organizations (NGOs) who are critical to helping develop, distribute, and market medicines in the US and globally.

Population(s) Served
Women and girls
Women and girls
Women and girls

Where we work

Our results

SOURCE: Self-reported by organization

How does this organization measure their results? It's a hard question but an important one.

Number of products distributed

This metric is no longer tracked.
Totals By Year
Related Program

Conducting pharmaceutical development to bring new medicines to market

Type of Metric

Output - describing our activities and reach

Direction of Success

Holding steady

Context Notes

To date, in collaboration with our commercial partner, we have made our hormonal IUD available to more than 1.2 million women throughout the United States.

Our Sustainable Development Goals

SOURCE: Self-reported by organization

Learn more about Sustainable Development Goals.

Goals & Strategy

SOURCE: Self-reported by organization

Learn about the organization's key goals, strategies, capabilities, and progress.

Charting impact

Four powerful questions that require reflection about what really matters - results.

Since our founding in 2009, we have learned critical lessons that have informed our priorities for the next chapter in our pursuit of equitable access. Complex problems require multi-faceted, long-term solutions. As a social enterprise, we are driven to help make equitable access to medicines a reality for women. Our organization has developed momentum to address one of the most pressing issues that plague our current system – the high cost of drugs that prohibits access for many women. We will continue engaging with stakeholders and philanthropic donors to bring new and expanded resources to our work in product development, policy advocacy, and public sector engagement.

Key Priorities:

1. Grow Our Impact: Expand the portfolio of women's health products that increase access and/or healthcare choice

2. Deliver on Medicines360's Promise: Expand AVIBELA's global impact

3. Capitalize on Our Success: Maximize our impact and act as a catalyst for change

4. Create Points of Leverage In the Community: Develop strategic relationships to acquire pipeline products and capital for R&D

How we listen

SOURCE: Self-reported by organization

Seeking feedback from people served makes programs more responsive and effective. Here’s how this organization is listening.

done We shared information about our current feedback practices.
  • How is your organization using feedback from the people you serve?

  • Which of the following feedback practices does your organization routinely carry out?

  • What challenges does the organization face when collecting feedback?


Fiscal year: Jan 01 - Dec 31
Financial documents
2021 Medicines360 and Subsidiaries
done  Yes, financials were audited by an independent accountant. info

Revenue vs. expenses:  breakdown

SOURCE: IRS Form 990 info
Note: When component data are not available, the graph displays the total Revenue and/or Expense values.

Liquidity in 2022 info

SOURCE: IRS Form 990


Average of 8.79 over 10 years

Months of cash in 2022 info

SOURCE: IRS Form 990


Average of 13.7 over 10 years

Fringe rate in 2022 info

SOURCE: IRS Form 990


Average of 15% over 10 years

Funding sources info

Source: IRS Form 990

Assets & liabilities info

Source: IRS Form 990

Financial data

SOURCE: IRS Form 990


Revenue & expenses

Fiscal Year: Jan 01 - Dec 31

SOURCE: IRS Form 990 info

Fiscal year ending: cloud_download Download Data


Balance sheet

Fiscal Year: Jan 01 - Dec 31

SOURCE: IRS Form 990 info

The balance sheet gives a snapshot of the financial health of an organization at a particular point in time. An organization's total assets should generally exceed its total liabilities, or it cannot survive long, but the types of assets and liabilities must also be considered. For instance, an organization's current assets (cash, receivables, securities, etc.) should be sufficient to cover its current liabilities (payables, deferred revenue, current year loan, and note payments). Otherwise, the organization may face solvency problems. On the other hand, an organization whose cash and equivalents greatly exceed its current liabilities might not be putting its money to best use.

Fiscal year ending: cloud_download Download Data


Financial trends analysis Glossary & formula definitions

Fiscal Year: Jan 01 - Dec 31

SOURCE: IRS Form 990 info

This snapshot of MEDICINES360’s financial trends applies Nonprofit Finance Fund® analysis to data hosted by GuideStar. While it highlights the data that matter most, remember that context is key – numbers only tell part of any story.

Created in partnership with

Business model indicators

Profitability info 2018 2019 2020 2021 2022
Unrestricted surplus (deficit) before depreciation -$8,543,831 $27,912,004 -$5,230,488 -$6,155,270 -$14,851,818
As % of expenses -40.5% 118.4% -22.8% -27.6% -80.0%
Unrestricted surplus (deficit) after depreciation -$8,788,818 $27,670,910 -$5,577,826 -$6,442,323 -$15,036,993
As % of expenses -41.2% 116.2% -23.9% -28.5% -80.2%
Revenue composition info
Total revenue (unrestricted & restricted) $16,684,261 $17,400,453 $12,024,199 $24,675,342 $10,933,921
Total revenue, % change over prior year -28.5% 4.3% -30.9% 105.2% -55.7%
Program services revenue 52.7% 0.0% 0.0% 0.0% 0.0%
Membership dues 0.0% 0.0% 0.0% 0.0% 0.0%
Investment income 13.2% 12.8% 13.7% 4.3% 12.3%
Government grants 0.0% 0.0% 0.0% 0.0% 0.0%
All other grants and contributions 3.6% 45.9% 4.0% 0.1% 4.4%
Other revenue 30.5% 41.3% 82.3% 95.5% 83.3%
Expense composition info
Total expenses before depreciation $21,111,005 $23,572,193 $22,990,219 $22,301,887 $18,553,604
Total expenses, % change over prior year 26.9% 11.7% -2.5% -3.0% -16.8%
Personnel 37.0% 37.7% 43.5% 47.2% 54.8%
Professional fees 39.2% 36.0% 36.3% 34.7% 24.7%
Occupancy 2.3% 2.0% 2.3% 2.4% 3.1%
Interest 0.0% 0.0% 0.0% 0.0% 0.0%
Pass-through 0.1% 0.1% 0.0% 0.0% 0.0%
All other expenses 21.4% 24.2% 17.8% 15.7% 17.4%
Full cost components (estimated) info 2018 2019 2020 2021 2022
Total expenses (after depreciation) $21,355,992 $23,813,287 $23,337,557 $22,588,940 $18,738,779
One month of savings $1,759,250 $1,964,349 $1,915,852 $1,858,491 $1,546,134
Debt principal payment $0 $0 $0 $0 $0
Fixed asset additions $0 $590,484 $0 $327,162 $0
Total full costs (estimated) $23,115,242 $26,368,120 $25,253,409 $24,774,593 $20,284,913

Capital structure indicators

Liquidity info 2018 2019 2020 2021 2022
Months of cash 2.4 1.4 0.9 1.9 2.3
Months of cash and investments 46.2 43.3 40.9 38.6 33.3
Months of estimated liquid unrestricted net assets 32.9 43.4 41.7 39.5 37.8
Balance sheet composition info 2018 2019 2020 2021 2022
Cash $4,144,895 $2,804,283 $1,710,899 $3,494,867 $3,497,245
Investments $77,090,983 $82,295,121 $76,665,039 $68,172,800 $48,006,499
Receivables $3,666,563 $2,391,655 $3,257,831 $3,289,739 $3,001,043
Gross land, buildings, equipment (LBE) $2,243,424 $2,840,855 $2,836,767 $2,281,555 $2,444,550
Accumulated depreciation (as a % of LBE) 73.0% 66.4% 78.3% 71.3% 74.4%
Liabilities (as a % of assets) 32.3% 3.9% 4.5% 5.1% 8.9%
Unrestricted net assets $58,462,049 $86,132,959 $80,555,133 $74,112,810 $59,075,817
Temporarily restricted net assets $500,940 N/A N/A N/A N/A
Permanently restricted net assets $0 N/A N/A N/A N/A
Total restricted net assets $500,940 $0 $0 $0 $164,971
Total net assets $58,962,989 $86,132,959 $80,555,133 $74,112,810 $59,240,788

Key data checks

Key data checks info 2018 2019 2020 2021 2022
Material data errors No No No No No


The people, governance practices, and partners that make the organization tick.

Letter of Determination is not available for this organization
Form 1023/1024 is not available for this organization

Principal Officer

Andrea Olariu, MD, PhD

Andrea Olariu, MD, PhD is Chief Executive Officer (CEO) of Medicines360 (Company). Since joining Company in 2010, Dr. Olariu has held several key roles for the organization. During her time as Chief Operations Officer (COO), Dr. Olariu oversaw Clinical/Medical and Regulatory Affairs, Product Development, and the Quality Department. Prior to her appointment as CEO for Medicines360, Dr. Olariu served as CEO for CuraePharma360. In her tenure at Medicines360, Dr. Olariu led the development, approval and product expansion strategy for Company’s hormonal IUD. Dr. Olariu has extensive experience designing and conducting clinical trials from proof-of-concept to large pivotal Phase 3 studies. Before joining Company, Dr. Olariu developed and implemented clinical/medical and regulatory strategies for several medical devices that received approval in the United States, Canada, and the European Union. Prior to moving to the US, Dr. Olariu spent over 15 years working in academia, as an Ass

Number of employees

Source: IRS Form 990


Officers, directors, trustees, and key employees

SOURCE: IRS Form 990

Show data for fiscal year
Compensation data
Download up to 5 most recent years of officer and director compensation data for this organization


Highest paid employees

SOURCE: IRS Form 990

Show data for fiscal year
Compensation data
Download up to 5 most recent years of highest paid employee data for this organization


Board of directors
as of 01/31/2024
SOURCE: Self-reported by organization
Board of directors data
Download the most recent year of board of directors data for this organization
Board chair

Leslie Benet, PhD

Ann Barber

Karen Dawes

Mike Dorsey

Lisa David

Organizational demographics

SOURCE: Self-reported; last updated 1/31/2024

Who works and leads organizations that serve our diverse communities? Candid partnered with CHANGE Philanthropy on this demographic section.


The organization's leader identifies as:

Gender identity

Race & ethnicity

No data

Gender identity

Transgender Identity

Sexual orientation

No data


No data

Equity strategies

Last updated: 03/30/2023

GuideStar partnered with Equity in the Center - an organization that works to shift mindsets, practices, and systems to increase racial equity - to create this section. Learn more

  • We review compensation data across the organization (and by staff levels) to identify disparities by race.
  • We employ non-traditional ways of gathering feedback on programs and trainings, which may include interviews, roundtables, and external reviews with/by community stakeholders.
  • We have long-term strategic plans and measurable goals for creating a culture such that one’s race identity has no influence on how they fare within the organization.


Fiscal year ending

Professional fundraisers

Fiscal year ending

SOURCE: IRS Form 990 Schedule G

Solicitation activities
Gross receipts from fundraising
Retained by organization
Paid to fundraiser